Hidden immunotherapy targets challenge dogma (Q36184951)

12 August 2017

Hidden immunotherapy targets challenge dogma (English)

1 reference

12 August 2017

1 reference

1

Soldano Ferrone

1 reference

PMCID

3426280

12 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

Science Translational Medicine

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

99

1 reference

12 August 2017

99ps38

1 reference

Targeting intracellular oncoproteins with antibody therapy or vaccination

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Cells of origin in cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Monoclonal antibodies: versatile platforms for cancer immunotherapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Monoclonal antibodies for cancer immunotherapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3426280

10.1126/SCITRANSLMED.3002821

1 October 2017

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

PMCID

3426280